Phosphatidylinositol kinase (PI3K) activation produces phosphatidylinositol trisphosphate, which acts as a second messenger leading to the activation of Akt, which in turn interacts with various substrates to regulate cell proliferation, differentiation, apoptosis and migration. PI3K signaling pathway is involved in a variety of tumorigenesis in vivo (e.g., lung, intestinal, breast, prostate, etc.), and for NSCLC, mutation or abnormal amplification of PIK3CA The incidence is about 5-7%, with a slightly different rate for squamous and non-squamous cancers, with a slightly higher rate of about 10% for squamous cancers and about 2-5% for non-squamous cancers. Currently, PI3K/AKT/mTOR inhibitors are still in clinical trials, and the representative drugs are BKM-120, BEZ235 and XL-147. BKM120 is an oral Pan-class1 PI3K inhibitor, and preclinical and phase I clinical studies have shown its antitumor activity against malignant tumors with PI3KCA mutation or amplification, PTEN mutation or deletion. activity. The ongoing D2201 study proposes to compare the efficacy and safety of BKM120 versus docetaxel or pemetrexed in NSCLC patients with PIK3CA or PTEN mutations who have failed first-line chemotherapy. No further study data have been published.